PatientsVille

Incontinence Medical Research Studies

View, Report and Compare Drug Side Effects Over 350,000 side effects reported

Up-to-date List of Incontinence Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Changes in the number of urge urinary Incontinence episodes per 24 hours between baseline and week 12; Percent change in the mean number of urge urinary Incontinence episodes per 24 hours; Change in the mean number of urge urinary Incontinence episodes per 24 hours; Change in the mean frequency of urination per 24 hours; Percent change in the mean frequency of urination; Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours; Change in the mean number of severe urgency episodes per 24 hours; Changes in overactive bladder symptom score (OABSS) questionnaire; Changes in short urogenital distress inventory (UDI-6); Changes in short Incontinence impact questionnaire (IIQ-7); Safety assessed by the incidence and severity of side effects

To evaluate the use of imodium as tablets or syrup in the treatment of faecal Incontinence in order to improve the scores of patients with faecal Incontinence as seen with continence and quality of life questionnaires; To reduce to number of patients suffering from faecal Incontinence; Number of episodes of total, urge and passive Incontinence; Total number of patient incontinent days; Use of pads and other medications; Ability to defer defaecation; Adverse effects relating to medication; Determining the direct medical costs, direct non-medical costs, indirect non-medical costs associated with the treatment of Faecal Incontinence, and cost effectiveness of treatment with syrup and tablets

The primary endpoint is comparison of median Incontinence score of VAIZEY in the two arms after 6 months.; Incontinence scores in the two arms after 6/8 weeks and 6 month, transitional anal Incontinence after delivery urinary Incontinence 6 and 12 month after the delivery, sexual score(IFSI)global morbidity between the two arms after anal endoscopy

Change in International Consultation on Incontinence Questionnaire: Female Lower Urinary Tract Symptoms (FLUTS); Change in International Consultation on Incontinence Questionnaire - Short form score; Change in pad weight on a standardized 20 minute pad test; Change in International Consultation on Incontinence Questionnaire Quality of Life module score

improvement in subjective and objective measures of urinary Incontinence; assessment of pre-treatment predictors of success or failure of treatment; assessment of pre-treatment predictors of requirement for alternative treatment

Average number of fecal Incontinence episodes; Overall cost for the health care system; Respective complications of the two therapeutic approaches; Functional results at 6 and 12 months, compared with baseline; Quality of life and overall satisfaction; Anorectal manometry data

Evaluate the efficacy of NRL001 in faecal Incontinence by assessing the improvement of the Incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score; To provide data on the efficacy of NRL001 in patients with faecal Incontinence over an 8 week treatment period; To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo; To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events; To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies; To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks; To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks

Change in the ability to contract the pelvic floor muscles from baseline to the midpoint and completion of the study; Change in the number of incontinent episodes per week from baseline to the midpoint and conclusion of the study; Change in quality of life from the baseline to the midpoint and completion of the study

Percentage of change from baseline in 72-h Incontinence episode frequency (IEF) (week 12); Percentage of change from baseline in 72-h IEF; Percentage of participants with ≥50% decrease in average 72-h Incontinence episode frequency; Change from baseline in 72-h Incontinence episode frequency; Change from baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score; Change from baseline in the amount of urine leakage; Change from baseline in average 72-h urgencies/urination/nocturia episodes; Change from the baseline in the number of pads used in one week; Percentage of change from the baseline in 72-h IEF of subgroups; Satisfaction degree; Patient global impression improvement; Electroacupuncture acceptance assessment

Difference in the baseline urinary NGF level between patients with and without urgency Incontinence at 6 months after midurethral slings; Baselinec cut-off value of urinary NGF level which can predict the patients whose urgency Incontinence will be cured and whose urgency Incontinence will not be cured.; Difference in urinary NGF level between pure SUI and MUI patients; Changes in OAB symptoms (including urgency Incontinence) and SUI after midurethral slings; Correlation between changes in urinary NGF and OAB symptoms (including urgency Incontinence) after midurethral slings

These studies may lead to new treatments and are adding insight into Incontinence etiology and treatment.

A major focus of Incontinence research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.